TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37340264

Group type: EXPERIMENTAL
Intervention: Nudge arms (various combinations of brief messages based on behavioral science)
Number of subjects: 27540

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 27540
Study: 37340268

Group type: EXPERIMENTAL
Intervention: Medical scribes in cardiology
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Medical scribes in orthopedics
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Medical scribes in both cardiology and orthopedics
Number of subjects: 18
Study: 37340300

Group type: EXPERIMENTAL
Intervention: Education (phone health education session on day 1)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Control (no health education)
Number of subjects: 536
Study: 37340306

Group type: EXPERIMENTAL
Intervention: Food supplement + PFMT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo + PFMT
Number of subjects: 32
Study: 37340318

Group type: EXPERIMENTAL
Intervention: Invasive markers of mitochondrial capacity (citrate synthase activity, mitochondrial DNA copy number, TOMM20, VDAC, protein content for complex I-V of the oxidative phosphorylation system)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Noninvasive assessments of mitochondrial capacity (PCr recovery postexercise)
Number of subjects: 19
Study: 37340369

Group type: EXPERIMENTAL
Intervention: Compression therapy using surgical gloves
Number of subjects: 104
Study: 37340371

Group type: EXPERIMENTAL
Intervention: Minimal-OS with r-FSH
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Minimal-OS with u-HMG
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mild-OS with r-FSH
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mild-OS with u-HMG
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups (including controls)
Number of subjects: 120
Study: 37340397

Group type: EXPERIMENTAL
Intervention: Low-dose chemotherapy (Ara-C) administered at home by parents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home chemotherapy intervention
Number of subjects: 0
Study: 37340439

Group type: EXPERIMENTAL
Intervention: MI-oriented adjunctive treatment (three individual therapy sessions and a self-help manual)
Number of subjects: 65

Group type: COMPARATOR
Intervention: CBT-oriented adjunctive treatment (three individual therapy sessions and a self-help manual)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both MI and CBT treatments
Number of subjects: 65
Study: 37340492

Group type: EXPERIMENTAL
Intervention: Tech-CBT intervention
Number of subjects: 70
Study: 37340664

Group type: EXPERIMENTAL
Intervention: Primary infection in seronegative girls
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Increase in anti-CMV antibody in seropositive girls
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: CMV DNA shedding in urine
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Overall CMV infection during follow-up
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Reinfection or reactivation rates
Number of subjects: 363
Study: 37340832

Group type: EXPERIMENTAL
Intervention: Daratumumab with dexamethasone
Number of subjects: 0
Study: 37341028

Group type: EXPERIMENTAL
Intervention: TAU and the App (App Group)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: TAU and the App + a commercial discount (App + Discount Group)
Number of subjects: 73

Group type: COMPARATOR
Intervention: TAU (Control Group)
Number of subjects: 73
Study: 37341164

Group type: EXPERIMENTAL
Intervention: CPI-613
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (surgical cohort)
Number of subjects: 20
Study: 37341189

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulins (ATG)
Number of subjects: 1413
Study: 37341243

Group type: EXPERIMENTAL
Intervention: IDP-126 gel (clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Dyad gels (1 of the 3 dyad gels, phase 2 only)
Number of subjects: 1020
Study: 37341351

Group type: EXPERIMENTAL
Intervention: Cold haemostasis during tonsillectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hot diathermia during tonsillectomy
Number of subjects: 0
Study: 37341530

Group type: EXPERIMENTAL
Intervention: Nanoparticle-mediated therapeutic approaches to the myocardium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nanoscience and nanoparticle-mediated approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nanoparticle-mediated tissue-targeted therapies
Number of subjects: 0
Study: 37341586

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 37341778

Group type: EXPERIMENTAL
Intervention: Ixazomib plus Lenalidomide and Dexamethasone (IRd)
Number of subjects: 45
Study: 37341915

Group type: EXPERIMENTAL
Intervention: Dalcinonacog alfa (DalcA) at a dose of 100 IU/kg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalcinonacog alfa (DalcA) at a dose of 125 IU/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalcinonacog alfa (DalcA) at a dose of 150 IU/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalcinonacog alfa (DalcA) at a dose escalation to 150 IU/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalcinonacog alfa (DalcA) at a dose escalation to 200 IU/kg
Number of subjects: 0
Study: 37341961

Group type: EXPERIMENTAL
Intervention: Secukinumab low dose (LD; 75/75/150 mg)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Secukinumab high dose (HD; 75/150/300 mg)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 198

Group type: COMPARATOR
Intervention: Etanercept (0.8 mg/kg)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Adult patients receiving secukinumab
Number of subjects: 198
Study: 37342018

Group type: EXPERIMENTAL
Intervention: Transfascial (TF) mesh fixation
Number of subjects: 325

Group type: COMPARATOR
Intervention: No mesh fixation (sham incisions)
Number of subjects: 325
Study: 37342036

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sleep hygiene (control)
Number of subjects: 67
Study: 37342040

Group type: EXPERIMENTAL
Intervention: High-definition Cathodal Direct Current Stimulation (HD C-tDCS) at 1 mA for 20 minutes and 2 mA for 20 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-definition Cathodal Direct Current Stimulation (HD C-tDCS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study: 37342080

Group type: EXPERIMENTAL
Intervention: RealConsent (internet-based intervention)
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: RealConsent (internet-based intervention) with 100% dosage
Number of subjects: 881

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 881
Study: 37342086

Group type: EXPERIMENTAL
Intervention: Online guided self-help intervention SOPHIE (8-week duration)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Care-as-usual control group
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Online guided self-help intervention SOPHIE
Number of subjects: 222
Study: 37342189

Group type: EXPERIMENTAL
Intervention: RRx-001 + RT + TMZ
Number of subjects: 16
Study: 37342313

Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 48

Group type: COMPARATOR
Intervention: MVA
Number of subjects: 48
Study: 37342359

Group type: COMPARATOR
Intervention: Surgical mask (ASTM Level 3 disposable surgical mask)
Number of subjects: 119
Study: 37342495

Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuff pressure monitoring during otorhinolaryngologic surgery
Number of subjects: 199
Study: 37342775

Group type: EXPERIMENTAL
Intervention: 1-week auto-CPAP treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-CPAP treatment
Number of subjects: 32
Study: 37342862

Group type: EXPERIMENTAL
Intervention: Premium hearing aids
Number of subjects: 190

Group type: COMPARATOR
Intervention: Basic hearing aids
Number of subjects: 190
Study: 37342923

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 795

Group type: COMPARATOR
Intervention: Ritonavir-boosted PI
Number of subjects: 795
Study: 37342922

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-tacrolimus-mycophenolate mofetil (experimental prophylaxis)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Tacrolimus-methotrexate (standard prophylaxis)
Number of subjects: 431
Study: 37343084

Group type: EXPERIMENTAL
Intervention: Microdialysis and ambulatory fraction collector for measuring tissue adrenal steroids
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Mathematical and computational methods for quantifying interindividual variability
Number of subjects: 214

Group type: COMPARATOR
Intervention: Comparison of tissue measurements against plasma measurements
Number of subjects: 214
Study: 37343145

Group type: EXPERIMENTAL
Intervention: Tanezumab 20 mg
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 37343335

Group type: EXPERIMENTAL
Intervention: PUMAS (mindfulness-based intervention)
Number of subjects: 12
Study: 37343576

Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution (Plasma-Lyte 148)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Saline (0·9% sodium chloride)
Number of subjects: 808
Study: 37343623

Group type: EXPERIMENTAL
Intervention: Brolucizumab treatment (Beovu, Novartis)
Number of subjects: 505
Study: 37343625

Group type: EXPERIMENTAL
Intervention: 10-μg bimatoprost implant
Number of subjects: 31
Study: 37343695

Group type: EXPERIMENTAL
Intervention: Family history of postpartum hemorrhage
Number of subjects: 16382

Group type: EXPERIMENTAL
Intervention: Personal transfusion history
Number of subjects: 16382

Group type: EXPERIMENTAL
Intervention: Use of oxytocin during labor
Number of subjects: 16382

Group type: EXPERIMENTAL
Intervention: Smoking during pregnancy
Number of subjects: 16382

Group type: EXPERIMENTAL
Intervention: Intrauterine growth restriction
Number of subjects: 16382
Study: 37343745

Group type: EXPERIMENTAL
Intervention: FN-EDB assay in IPF patients
Number of subjects: 133

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 133
Study: 37344061

Group type: EXPERIMENTAL
Intervention: Oral lutein and zeaxanthin supplementation for three months
Number of subjects: 21
Study: 37344080

Group type: EXPERIMENTAL
Intervention: Pecan-enriched diet (68 g of pecans/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (avoid all nuts)
Number of subjects: 44
Study: 37344091

Group type: EXPERIMENTAL
Intervention: High avocado allotment (14 avocados per week)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low avocado allotment (3 avocados per week)
Number of subjects: 90
Study: 37344262

Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 694

Group type: COMPARATOR
Intervention: PCV13 (13-valent pneumococcal conjugate vaccine)
Number of subjects: 694
Study: 37344265

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster dose (5 × 10^10 viral particles)
Number of subjects: 0
Study: 37344337

Group type: EXPERIMENTAL
Intervention: Perioperative pain neuroscience education (PPNE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional biomedical education (PBE)
Number of subjects: 120
Study: 37344340

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 765
Study: 37344474

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks) plus weekly paclitaxel (80 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks) plus flat-dose capecitabine
Number of subjects: 0
Study: 37344582

Group type: EXPERIMENTAL
Intervention: Deep Learning Assistant for Retinoblastoma Monitoring (DLA-RB) algorithm
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combination of ophthalmologists and DLA-RB
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: DLA-RB-based diagnosis mode
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: DLA-RB
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: DLA-RB-based screening and surveillance
Number of subjects: 103
Study: 37344745

Group type: EXPERIMENTAL
Intervention: LUCAS scan
Number of subjects: 198
Study: 37344751

Group type: EXPERIMENTAL
Intervention: Inhaled PUR1900 (itraconazole) at doses up to 40 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam (5 mg) co-administered with inhaled PUR1900
Number of subjects: 0
Study: 37344778

Group type: EXPERIMENTAL
Intervention: GuG-Auf intervention (12 sessions)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: GuG-Auf intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 135
Study: 37344780

Group type: EXPERIMENTAL
Intervention: Robotic nipple-sparing mastectomy (RNSM)
Number of subjects: 2000
Study: 37344789

Group type: EXPERIMENTAL
Intervention: Open Discontinuation (OD)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Hidden Discontinuation (HD)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Open Continuation (OC)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Hidden Continuation (HC)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 196
Study: 37344801

Group type: EXPERIMENTAL
Intervention: Fluid administration of 250 ml of crystalloid fluid
Number of subjects: 69

Group type: COMPARATOR
Intervention: Fluid challenges (36 positive and 68 negative)
Number of subjects: 69
Study: 37344825

Group type: EXPERIMENTAL
Intervention: Subtype 1 (n=105, 45.3%)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Subtype 2 (n=127, 54.7%)
Number of subjects: 232

Group type: COMPARATOR
Intervention: 52-gene signature risk groups
Number of subjects: 232
Study: 37344887

Group type: EXPERIMENTAL
Intervention: Gold nanoparticles and gold nanorods
Number of subjects: 0
Study: 37344895

Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b at a dosing regimen of 250-350-500 μg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Approved dosing schema of ropeginterferon alfa-2b (starting dose of 100 µg)
Number of subjects: 49
Study: 37344997

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.05 mg/kg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 37345084

Group type: EXPERIMENTAL
Intervention: Preoperative IMRT of 45-50 Gy with a simultaneous integrated boost of 50-56 Gy, followed by surgery and IORT.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Preoperative IMRT of > 50 Gy plus IORT boost.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Not applicable (no control group).
Number of subjects: 37
Study: 37345196

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (JAK1/JAK2 inhibitor)
Number of subjects: 1120
Study: 37345256

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous culture-expanded adipose-derived mesenchymal stem cells (ADMSCs)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 37345518

Group type: EXPERIMENTAL
Intervention: HT with pretransplant MCS
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: HT without pretransplant MCS
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Long-term MCS
Number of subjects: 227
Study: 37345544

Group type: EXPERIMENTAL
Intervention: Group psychotherapy for RAS with moderate depressive symptoms
Number of subjects: 0
Study: 37345627

Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 0
Study: 37345645

Group type: EXPERIMENTAL
Intervention: Evobrutinib
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 37345661

Group type: EXPERIMENTAL
Intervention: Dietary fat restriction
Number of subjects: 17

Group type: COMPARATOR
Intervention: Eucaloric baseline diet
Number of subjects: 17
Study: 37345754

Group type: COMPARATOR
Intervention: Baseline model without WMH
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Model with WMH included
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Incident stroke or cognitive decline
Number of subjects: 727
Study: 37345805

Group type: EXPERIMENTAL
Intervention: Pharmacologic-mediated hyperemia with intracoronary adenosine or nitroprusside (n=30)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Flow-mediated hyperemia (n=37)
Number of subjects: 67
Study: 37345815

Group type: EXPERIMENTAL
Intervention: Internet participation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noninternet participation
Number of subjects: 0
Study: 37345813

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve edge-to-edge repair
Number of subjects: 2534
Study: 37345834

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 11551

Group type: COMPARATOR
Intervention: Standard deviation of SBP variability
Number of subjects: 11551

Group type: COMPARATOR
Intervention: SBP variability
Number of subjects: 11551
Study: 37345876

Group type: EXPERIMENTAL
Intervention: Bulevirtide 2 mg per day for 144 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bulevirtide 10 mg per day for 144 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no treatment for 48 weeks followed by bulevirtide 10 mg per day for 96 weeks)
Number of subjects: 150
Study: 37345996

Group type: EXPERIMENTAL
Intervention: Combination intervention (acute HIV testing, contract partner notification (cPN), and social contact referral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contract partner notification (cPN) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive partner notification (pPN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 0
Study: 37346892

Group type: EXPERIMENTAL
Intervention: Crawling on a mini-skateboard (Crawli)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Prone positioning control (Mattress)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 44
Study: 37346899

Group type: EXPERIMENTAL
Intervention: Gothenburg Treatment for Gaming Disorder (GOT-TO-GO) manual; a 15-week cognitive behavioral therapy treatment for GD
Number of subjects: 0
Study: 37347015

Group type: EXPERIMENTAL
Intervention: Osteoconductive scaffold augmentation at the femoral tunnel aperture
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group with femoral fixation using cortical suspension fixation and secondary press-fit fixation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Osteoconductive scaffold intervention
Number of subjects: 56
Study: 37347294

Group type: EXPERIMENTAL
Intervention: Single-level fusion surgery
Number of subjects: 38
Study: 37347370

Group type: EXPERIMENTAL
Intervention: Inhaled IFN-α2b 2.5 MIU twice daily for 10 days (n = 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled IFN-α2b 5.0 MIU twice daily for 10 days (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n = 3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled IFN-α2b (both doses)
Number of subjects: 12
Study: 37347393

Group type: EXPERIMENTAL
Intervention: Nirogacestat
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 37347517

Group type: EXPERIMENTAL
Intervention: Dementia CHAT (D-CHAT)
Number of subjects: 0
Study: 37347518

Group type: EXPERIMENTAL
Intervention: Interactive multimedia web-based video consent
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional written consent document
Number of subjects: 79
Study: 37347521

Group type: EXPERIMENTAL
Intervention: Smartphone ownership and usage patterns among enrolled women
Number of subjects: 639
Study: 37347538

Group type: EXPERIMENTAL
Intervention: Scheduled morning assessments
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Random assessments
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Younger participants
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Full-time employed participants
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Participants who dropped out of the study
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: White participants
Number of subjects: 257
Study: 37347553

Group type: EXPERIMENTAL
Intervention: Specific Cryptosporidium antigens (Cp23, Cp17, Gp900, CpSMP1, CpMuc8, CpCorA, CpCCDC1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibody responses
Number of subjects: 0
Study: 37347686

Group type: EXPERIMENTAL
Intervention: NCI Natural History and Biospecimens Acquisitions Study for Children and Adults with Rare Solid Tumors protocol (NCT03739827)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multidisciplinary expert clinic
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Literature review of pediatric PDC and DC
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multimodal approaches
Number of subjects: 12
Study: 37347913

Group type: EXPERIMENTAL
Intervention: In-home telehealth cognitive behavioral treatment
Number of subjects: 268

Group type: COMPARATOR
Intervention: In-person cognitive behavioral treatment
Number of subjects: 268
Study: 37347964

Group type: EXPERIMENTAL
Intervention: 30-min nap
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2-hr nap
Number of subjects: 26

Group type: COMPARATOR
Intervention: No-nap condition
Number of subjects: 26
Study: 37347968

Group type: EXPERIMENTAL
Intervention: 30-min nap opportunity
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 2-hr nap opportunity
Number of subjects: 28

Group type: COMPARATOR
Intervention: No-nap
Number of subjects: 28
Study: 37347984

Group type: EXPERIMENTAL
Intervention: Cervical spinal manipulation (high-velocity, low-amplitude technique)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham intervention (manual contact under the head)
Number of subjects: 44
Study: 37348019

Group type: EXPERIMENTAL
Intervention: Amcenestrant
Number of subjects: 290

Group type: COMPARATOR
Intervention: Standard endocrine treatment of physician's choice (TPC)
Number of subjects: 290
Study: 37348035

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study: 37348093

Group type: EXPERIMENTAL
Intervention: 12 mm Hg insufflation pressure (experimental group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 15 mm Hg insufflation pressure (standard group)
Number of subjects: 80